A randomized controlled trial of adjuvant immunotherapy (murine monoclonal antibody 494/32) in resectable pancreatic cancer
Open Access
- 1 October 1991
- Vol. 68 (7), 1507-1512
- https://doi.org/10.1002/1097-0142(19911001)68:7<1507::aid-cncr2820680707>3.0.co;2-0
Abstract
No abstract availableKeywords
This publication has 30 references indexed in Scilit:
- Immunotherapy of Pancreatic Cancer with Monoclonal Antibody BW 494: Results from a Multicentric Phase I–II TrialPublished by Springer Nature ,1989
- Whatʼs New In General SurgeryAnnals of Surgery, 1988
- Monocyte-Related Functions Expressed in Cell Lines Established From Human Pancreatic Adenocarcinoma. 11. Inhibition of Stimulated Activity by Monoclonal Antibodies Reacting With Surface Antigens on Tumor CellsPancreas, 1988
- Immuntherapie des fortgeschrittenen Pankreaskarzinoms mit dem monoklonalen Antikörper BW 494Deutsche Medizinische Wochenschrift (1946), 1988
- Cancer of the pancreas: 50 years of surgeryCancer, 1987
- Monocyte-Related Functions Expressed in Cell Lines Established from Human Pancreatic Adenocarcinoma. I. Comparative Analysis of Endocytotic Activity, Lysosomal Enzyme Secretion, and Superoxide Anion ProductionPancreas, 1987
- A monoclonal antibody with binding and inhibiting activity towards human pancreatic carcinoma cellsCancer Immunology, Immunotherapy, 1986
- Das PankreaskarzinomPublished by Springer Nature ,1986
- PHASE-I CLINICAL TRIAL OF MONOCLONAL ANTIBODY IN TREATMENT OF GASTROINTESTINAL TUMOURSThe Lancet, 1982
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958